-
1 Comment
China Health Group Inc is currently in a long term downtrend where the price is trading 11.0% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
China Health Group Inc's total revenue rose by 33.9% to $32M since the same quarter in the previous year.
Its net income has increased by 117.9% to $28M since the same quarter in the previous year.
Finally, its free cash flow grew by 741.9% to $3M since the same quarter in the previous year.
Based on the above factors, China Health Group Inc gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Exchange | HK |
CurrencyCode | HKD |
Industry | Diagnostics & Research |
ISIN | KYG2117N1088 |
Market Cap | 154M |
---|---|
PE Ratio | 7.75 |
Beta | 0.19 |
Target Price | None |
Dividend Yield | None |
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People's Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 8225.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025